Paclitaxel

Paclitaxel is an anticancer medicine belonging to the taxane class of chemotherapy drugs. It works by targeting microtubules, which are structures that help cells maintain their shape and divide. Paclitaxel stabilises these structures and prevents them from breaking down normally during cell division, disrupting the process and leading to the death of susceptible cancer cells. Because it can also affect healthy cells that divide or function rapidly, treatment may cause side effects involving the bone marrow, nerves, digestive system and hair follicles. Conventional paclitaxel is generally administered by intravenous infusion under the supervision of an oncology team. Albumin-bound paclitaxel is a separate formulation with different preparation instructions, dosing schedules and precautions; the two formulations should not be considered automatically interchangeable. Paclitaxel is used alone or in combination with other anticancer medicines, depending on the cancer type, disease stage and previous treatment. It has an established role in the treatment of several solid tumours, including breast, ovarian and non-small-cell lung cancers. Certain formulations and regimens also have indications in other cancers. Treatment selection requires consideration of the patient's general condition, blood counts, liver function, nerve-related symptoms and other medicines. Close monitoring helps clinicians assess response, manage adverse effects and determine whether treatment adjustments are needed.

Paclitaxel was originally identified from the Pacific yew tree, Taxus brevifolia, during natural-product anticancer research. Its unusual ability to stabilise microtubules established a distinct mechanism of action among chemotherapy medicines and supported its development for multiple cancers. Paclitaxel entered clinical use in the United States in the early 1990s, with FDA approval for ovarian cancer in 1992, followed by additional indications and treatment combinations over subsequent years. The European Medicines Agency authorised the albumin-bound paclitaxel medicine Abraxane in 2008 for specified cancer indications, including metastatic breast cancer; its authorised uses were subsequently extended to include pancreatic adenocarcinoma and non-small-cell lung cancer in defined combinations. Conventional solvent-based paclitaxel and albumin-bound paclitaxel have different product information and approved regimens. Clinical development included trials evaluating paclitaxel alone and in combination with platinum-based chemotherapy, anthracyclines and other anticancer medicines. Approval status, available formulations and authorised indications vary between countries and individual products. In India, the current Central Drugs Standard Control Organisation requirements and the relevant product's approved prescribing information should be consulted to confirm locally authorised uses.

Paclitaxel is used to treat several cancers, with indications depending on the formulation, country-specific approval and treatment regimen. Conventional paclitaxel is used in ovarian cancer, breast cancer and non-small-cell lung cancer, either alone or in combination with other chemotherapy medicines. Depending on the approved product information, it may be used in advanced ovarian cancer with platinum-based treatment, in breast cancer following surgery or for advanced disease, and in non-small-cell lung cancer with a platinum medicine. It may also be used in selected patients with AIDS-related Kaposi's sarcoma when specified previous treatments have not worked. Albumin-bound paclitaxel has separate approved indications, including metastatic breast cancer after previous chemotherapy, metastatic pancreatic adenocarcinoma with gemcitabine, and non-small-cell lung cancer with carboplatin in defined clinical settings. These indications should not be assumed to apply identically to every paclitaxel product. Treatment may be given as monotherapy or in combination with other anticancer agents according to the cancer type, stage, prior treatment and patient's clinical condition. The decision to use paclitaxel should be made by an oncology specialist after reviewing the expected benefits, treatment alternatives and potential risks.

Paclitaxel is generally administered by intravenous infusion in a hospital or specialist oncology setting. The dose is commonly calculated using body surface area, although the precise method depends on the formulation and treatment protocol. Conventional paclitaxel may be administered at intervals such as every three weeks or weekly, depending on the cancer and whether it is used alone or with other medicines. Albumin-bound paclitaxel uses different schedules, including weekly administration in some treatment regimens, and must be prepared according to its own product instructions. Before each treatment, clinicians assess blood counts, liver function, peripheral neuropathy and other relevant clinical findings. Premedication is generally required with conventional solvent-based paclitaxel to reduce the risk of hypersensitivity reactions; premedication requirements differ for albumin-bound formulations and should follow their prescribing information. Treatment continues according to the planned number of cycles, cancer response, tolerability and any evidence of disease progression. Doses may be delayed, reduced or discontinued for significant toxicity or abnormal laboratory results. The formulation, infusion duration and preparation instructions must be checked carefully, as different paclitaxel products are not automatically interchangeable.

Common side effects of paclitaxel include hair loss, nausea, vomiting, diarrhoea, reduced appetite, tiredness, muscle pain and joint pain. Bone marrow suppression can lower white blood cell counts, increasing the risk of infection, and may also cause anaemia or reduced platelet counts. Peripheral neuropathy, which can cause tingling, numbness, burning sensations or pain in the hands and feet, is another important adverse effect and may worsen with cumulative exposure. Conventional paclitaxel may cause injection-site reactions or infusion-related hypersensitivity symptoms. The frequency and severity of side effects vary with the dose, formulation, schedule, other medicines and individual health factors. Many effects can be managed with supportive care, dose adjustments and close monitoring, but patients should report persistent symptoms, worsening numbness, unusual bruising or signs of infection promptly to their treatment team.

Important risks associated with paclitaxel include severe neutropenia, serious infections, significant hypersensitivity reactions, peripheral neuropathy and liver-related toxicity. Severe bone marrow suppression can sometimes require treatment delays, dose reductions or discontinuation. Conventional paclitaxel can cause serious infusion reactions, including breathing difficulty, low blood pressure and anaphylaxis; appropriate premedication and immediate access to emergency treatment are essential. Cardiac rhythm abnormalities and other cardiovascular events have also been reported. Patients with pre-existing neuropathy, impaired liver function or significant blood-count abnormalities may need additional assessment and modified treatment. Paclitaxel can harm a developing fetus, so pregnancy prevention and counselling about reproductive risks are important when applicable. Treatment should be withheld, adjusted or discontinued when clinically significant toxicity occurs, in accordance with the relevant prescribing information. Fever during chemotherapy, breathing difficulty, severe allergic symptoms or other signs of a serious infection require urgent medical assessment.

Before starting paclitaxel, clinicians should review the patient's medical history, previous chemotherapy exposure, allergies, complete blood count, liver function and any existing peripheral neuropathy. Dose adjustment or additional caution may be necessary in patients with hepatic impairment, low blood cell counts or significant nerve-related symptoms. Pregnancy should be avoided during treatment, and patients should receive appropriate counselling about fertility preservation and reproductive risks when relevant. Breastfeeding restrictions and the recommended contraception period should follow the specific product's prescribing information. Conventional paclitaxel contains formulation-specific excipients that may contribute to hypersensitivity reactions, whereas albumin-bound paclitaxel has different formulation characteristics and precautions. Drug interactions are clinically important: medicines that inhibit or induce CYP2C8 or CYP3A4 may alter paclitaxel exposure, while other chemotherapy agents can increase bone marrow suppression or nerve toxicity. Some combinations may also increase the risk of liver or cardiovascular complications. All prescription medicines, non-prescription products and supplements should be reviewed before treatment. Live vaccines may be inappropriate during significant chemotherapy-induced immunosuppression, and vaccination timing should be discussed with the oncology team.

Prescribers and pharmacists should verify the exact paclitaxel formulation, prescribed regimen, dose calculation and infusion instructions before every treatment. Conventional solvent-based paclitaxel and albumin-bound paclitaxel differ in formulation, preparation, premedication requirements and dosing, so substitution should not occur without an appropriate clinical review. Obtain baseline blood counts and liver function tests, assess existing neuropathy and review previous hypersensitivity reactions. Repeat laboratory testing at the intervals specified by the treatment protocol, and evaluate fever, infection symptoms, worsening numbness, unusual bruising or infusion reactions promptly. Confirm that the patient receives appropriate supportive care and understands when to seek urgent medical attention. Review concurrent medicines for interactions that may affect paclitaxel metabolism or compound toxicity. Follow the manufacturer's requirements for storage, dilution, administration equipment and safe handling of cytotoxic medicines. Treatment decisions should be coordinated across the oncology, nursing and pharmacy teams, with dose modifications based on the patient's clinical status, laboratory results and treatment tolerance.